Showing 421 - 440 results of 44,775 for search '(( 5 ((ng decrease) OR (mean decrease)) ) OR ( 50 ((ns decrease) OR (a decrease)) ))', query time: 0.92s Refine Results
  1. 421

    Decrease in Vitamin D Status in the Greenlandic Adult Population from 1987–2010 by Nina O. Nielsen (490187)

    Published 2014
    “…In all age-groups it decreased from 1987 to 2005–2010 (32%–58%). Low 25(OH)D3 concentrations (<50 nmol/L) were present in 77% of the 18–29 year old and decreased with age. …”
  2. 422

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
  3. 423

    CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells. by Elif Aplak (7430123)

    Published 2020
    “…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
  4. 424

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  5. 425
  6. 426
  7. 427
  8. 428
  9. 429
  10. 430

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  11. 431

    Decreasing ShcA expression enhances TGF-β-induced Smad signaling. by Baby Periyanayaki Muthusamy (838234)

    Published 2015
    “…(C) Subcellular localization of Smad2/3, assessed by immunofluorescence, in NMuMG or HaCaT cells, transfected with control or ShcA siRNA (siShc-a for NMuMG cells, siShc-c for HaCaT cells), in the absence of added TGF-β or in response to 2 ng/ml TGF-β for 60 min. (D, E) Decreasing ShcA expression, upon transfection of ShcA siRNA (siShc-a for NMuMG cells, siShc-c for HaCaT cells) but not control siRNA, enhances Smad3-mediated transcription, quantified by luciferase expression from a 4xSBE-luciferase reporter, in NMuMG (D) and HaCaT (E) cells, in the absence of or in response to 0.8 ng/ml TGF-β, or treated with SB431542, for 6 h. …”
  12. 432
  13. 433
  14. 434

    ku0063794 but not rapamycin decreased the TRPC6 mRNA levels in podocytes. by Fangrui Ding (659863)

    Published 2014
    “…<p>(A) ku0063794 (2 µmol/l) or rapamycin (50 nmol/l) was applied to evaluate the effects of mTORC1 and mTORC2 on TRPC6 in podocytes. …”
  15. 435
  16. 436
  17. 437
  18. 438
  19. 439
  20. 440